Citation:Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N 2003

From Cancer Guidelines Wiki

Citation


Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003 Feb 4;138(3):176-86 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12558356.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Is surveillance cost-effective for follow-up of patients with BO?Dr Louisa Gordoncompleted
For which populations is screening for BO cost-effective?Professor Jon Emery MA, MBBCh, FRACGP, MRCGP, DPhilcompleted
What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?David Whitemancompleted
Are there groups of patients with non-dysplastic BO that require more frequent surveillance?Dr Henry Tocompleted
Are there groups of patients with BO that can be discharged from surveillance?Conjoint Associate Professor Philip Craigcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Is surveillance cost-effective for follow-up of patients with BO?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is surveillance cost-effective for follow-up of patients with BO?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:For which populations is screening for BO cost-effective?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For which populations is screening for BO cost-effective?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Are there groups of patients with non-dysplastic BO that require more frequent surveillance?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Are there groups of patients with non-dysplastic BO that require more frequent surveillance?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Are there groups of patients with BO that can be discharged from surveillance?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Are there groups of patients with BO that can be discharged from surveillance?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. For which populations is screening for BO cost-effective?
  2. Is surveillance cost-effective for follow-up of patients with BO?